BioTuesdays

Tag - SVB Leerink

Minerva Surgical
Markets

Analysts start Minerva Surgical at OW, OP; PT $17

Piper Sandler and SVB Leerink launched coverage of Minerva Surgical (NASDAQ:UTRS) with “overweight” and “outperform” ratings, respectively, and price targets of $17. The stock closed at $9.62 on Nov. 15. Minerva, which...

November 16, 2021
Theseus Pharmaceuticals
Markets

SVB Leerink starts Theseus Pharma at OP; PT $28

SVB Leerink launched coverage of Theseus Pharmaceuticals (NASDAQ:THRX) with an “outperform” rating and $28 price target. The stock closed at $17.12 on Oct. 29. Theseus is a biopharmaceutical company focused on “pan...

November 1, 2021
Atea Pharmaceuticals
Markets

SVB Leerink cuts Atea Pharma PT to $20 from $60

SVB Leerink slashed its price target for Atea Pharmaceuticals (NASDAQ:AVIR) to $20 from $60 but maintained its “outperform” rating after the company’s Phase 2 MOONSONG trial in COVID-19 outpatients did not hit its...

October 20, 2021
Dice-Therapeutics
Markets

SVB Leerink starts DICE Therapeutics at OP; PT $46

SVB Leerink launched coverage of Dice Therapeutics (NASDAQ:DICE) with an “outperform” rating and $46 price target. The stock closed at $26.49 on Oct. 8. DICE is a biopharmaceutical company leveraging its proprietary...

October 11, 2021
ContraFect Logo
Markets

SVB Leerink starts ContraFect at OP; PT $14

SVB Leerink initiated coverage of ContraFect (NASDAQ:CFRX) with an “outperform” rating and sum-of-the-parts price target of $14. The stock closed at $3.90 on Sept. 8. Analyst Roanna Ruiz, Ph.D., writes that...

September 9, 2021
Aligos-Therapeutics
Markets

SVB Leerink starts Aligos Therapeutics at OP; PT $29

SVB Leerink initiated coverage of Aligos Therapeutics (NASDAQ:ALGS) with an “outperform” rating and $29 price target. The stock closed at $15.31 on Sept. 8. Analyst Roanna Ruiz, Ph.D., writes that Aligos is unique among...

September 9, 2021
scPharmaceuticals
Markets

SVB Leerink starts scPharmaceuticals at MP; PT $6

SVB Leerink launched coverage of scPharmaceuticals (NASDAQ:SCPH) with a “market perform” rating sum-of-the-parts PT of $6. The stock closed at $5.95 on Sept. 8. Analyst Roanna Ruiz, Ph.D., writes that, among other...

September 9, 2021
RxSight
Markets

Analysts start RxSight at buy

Analysts for BTIG and SVB Leerink launched coverage of RxSight (NASDAQ:RXST) with “buy” ratings and price targets of $28 and $20, respectively. The stock closed at $11.94 on Aug. 23. RxSight has developed the Light...

August 24, 2021